Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 2Active not recruiting 2Unknown 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Carcinoma, Non-Small-Cell Lung 47Breast Neoplasms 39Ovarian Neoplasms 35Triple Negative Breast Neoplasms 24Endometrial Neoplasms 20Stomach Neoplasms 19Squamous Cell Carcinoma of Head and Neck 17Fallopian Tube Neoplasms 17Lung Neoplasms 16Esophageal Squamous Cell Carcinoma 14Parkinson Disease 4, Autosomal Dominant Lewy Body 13Neoplasm Metastasis 13Esophageal Neoplasms 13Neoplasms 12Uterine Cervical Neoplasms 11Carcinoma, Ovarian Epithelial 10Head and Neck Neoplasms 7Recurrence 6Carcinoma 6Colorectal Neoplasms 5Adenocarcinoma 5Uterine Neoplasms 4Small Cell Lung Carcinoma 4Oropharyngeal Neoplasms 4Melanoma 4Carcinoma, Transitional Cell 4Advanced Solid Tumors 4Adenocarcinoma Of Esophagus 4Carcinoma, Squamous Cell 3Carcinoma, Renal Cell 3

Interventions

Trastuzumab 8pyrotinib 6pertuzumab 4Docetaxel 3Capecitabine 3tucatinib 2Paclitaxel 2Neoadjuvant Therapy 2trastuzumab deruxtecan 1neratinib 1inavolisib 1Taxoids 1Isovaleryl-CoA Dehydrogenase 1Injections 1Genetic Testing 1Drug Therapy 1Carboplatin 1Blood Specimen Collection 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × HER2-positive Breast Cancer × Paclitaxel × Clear all
NCT07377643 2026-02-25

IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer

Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

Phase 3 Recruiting
540 enrolled
Breast

HER2-positive Breast Cancer

NCT06992882 2025-07-18

A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)

Fudan University

Phase 3 Recruiting
2,306 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡